Want to join the conversation?
$BMY said CheckMate -026, a Phase 3 Study of Opdivo (nivolumab) in Treatment-Naive Patients with Advanced Non-Small Cell Lung Cancer, failed to meet the primary endpoint of progression-free survival. The company will complete a full evaluation of the CheckMate -026 data and work with investigators on the future presentation of the results.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.
$RAI has received a $47 billion take over offer from British tobacco giant British American Tobacco! This is huge!